Condition
Dentatorubral-Pallidoluysian Atrophy
Total Trials
4
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Active Not Recruiting2
Recruiting1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06706388Phase 1Active Not RecruitingPrimary
Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation
NCT07221760Phase 1Not Yet RecruitingPrimary
Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation
NCT07084311Phase 1Active Not RecruitingPrimary
Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation
NCT06273150RecruitingPrimary
Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study
Showing all 4 trials